leadf
logo-loader
viewOncimmune

Oncimmune welcomes independent validation of its lung blood test

The data were presented in detail at the recent American College of Chest Physicians (CHEST) annual meeting

Oncimmune -

Oncimmune Holdings PLC (LON:ONC) has welcomed the publication of abstracts from two clinical studies that provide “independent validation” of the company’s EarlyCDT Lung blood test.

The data were presented in detail at the recent American College of Chest Physicians (CHEST) annual meeting.

The first paper assessed the performance of the EarlyCDT Lung blood test in PANOPTIC clinical trial samples to identify potentially malignant indeterminate pulmonary nodules (growths in the lung).

The reported specificity was 93% and positive predictive value 74%, which Oncimmune said correlated with previous publications of the EarlyCDT Lung blood test.

The second paper looked at the use of two blood-based biomarker tests in tandem to reclassify the risk of indeterminate pulmonary nodules.

Researchers assessed the use of Nodify CDT (the US marketing name for EarlyCDT) with another test, called Nodify XL2.

The data revealed that “the combined testing strategy would have reduced delays in diagnosis of malignant nodules and helped reduce unnecessary procedures on benign nodules”.

In a statement, Oncimmune chief executive, Dr Adam Hill, said: "Whilst the EarlyCDT Lung blood test is underpinned by substantive evidence of its utility in IPN patients and reduction in unnecessary invasive procedures, I welcome this independent validation of the panel with the important PANOPTIC sample set, and confirmation of the utility of a combined rule-in and rule-out strategy in the US nodule clinic setting."

For more information click here

Quick facts: Oncimmune

Price: 162.5 GBX

AIM:ONC
Market: AIM
Market Cap: £103.25 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Oncimmune named herein, including the promotion by the Company of Oncimmune in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Oncimmune Holdings' collaborate with US based Augmenta Bioworks to profile...

Oncimmune Holdings PLC's (LON:ONC) Adam Hill tells Proactive London about their master service agreement with California-based immunotherapy specialist Augmenta Bioworks. This collaboration will profile patient plasma samples and assess treatment candidates discovered using the latter’s...

3 weeks, 3 days ago

2 min read